Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12632827 | 0.87 | HSD11B1 (0.40) | DRD2ALDH1A1MEN1KDM4EKMT2A | |
| SCHEMBL22731537 | 0.84 | HRH3 (0.39) | DRD2DRD3HTR4S1PR1S1PR3 | |
| SCHEMBL19011592 | 0.82 | S1PR1 (0.35) | DRD2DRD3HTR4S1PR1S1PR3 | |
| SCHEMBL10924619 | 0.82 | ALDH1A1 (0.39) | DRD2DRD3HRH3ALDH1A1KDM4E | |
| SCHEMBL11575418 | 0.82 | — | — | |
| SCHEMBL14116873 | 0.82 | HRH3 (0.50) | HTR4S1PR1S1PR3S1PR5HRH3 | |
| SCHEMBL14116862 | 0.82 | S1PR1 (0.40) | DRD2DRD3HTR4S1PR1S1PR3 | |
| SCHEMBL18199668 | 0.81 | HRH3 (0.33) | HTR4S1PR1S1PR3S1PR5HRH3 | |
| SCHEMBL19977411 | 0.79 | DRD2 (0.37) | DRD2DRD3HTR4S1PR1S1PR3 | |
| SCHEMBL10930283 | 0.78 | HSD11B1 (0.42) | DRD3HRH3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3159342-B1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/PI3K INHIBITOR | CISEN PHARMACEUTICAL CO LTD (CN) | 2020-08-05 | — | — | EP | disclosed |
| EP-3159341-B1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS PI3K INHIBITOR | CHAI TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-3130592-B1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2019-08-14 | — | — | EP | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-08-24 | — | — | US | disclosed |
| EP-3199530-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | Changzhou Yinsheng Pharmaceutical Co., Ltd. (CN) | 2017-08-02 | — | — | EP | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| EP-3170810-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | Cisen Pharmaceutical Co. Ltd. (CN) | 2017-05-24 | — | — | EP | disclosed |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| EP-3159342-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS MTOR/PI3K INHIBITOR | Cisen Pharmaceutical Co. Ltd. (CN) | 2017-04-26 | — | — | EP | disclosed |
| EP-3159341-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS PI3K INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2017-04-26 | — | — | EP | disclosed |
| EP-3147283-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | North China Pharmaceutical Company., Ltd. (CN) | 2017-03-29 | — | — | EP | disclosed |
| EP-3130592-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | F12, F10, F11 | DRD2 2694/4885DRD3 1665/4885HTR4 2285/4885 |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | DRD2 4730/4885DRD3 4427/4885HTR4 4669/4885 |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | GTF3C4, BRD4, CUL4B | DRD2 4665/4885DRD3 4729/4885HTR4 2268/4885 |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | PARP1, PARP2, PARP11 | DRD2 3721/4885DRD3 3807/4885HTR4 1070/4885 |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | PIK3CA, PIK3CD, PIP5K1B | DRD2 4007/4885DRD3 3748/4885HTR4 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.